294 related articles for article (PubMed ID: 32248194)
1. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
Sanchorawala V
Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Sanchorawala V; Boccadoro M; Gertz M; Hegenbart U; Kastritis E; Landau H; Mollee P; Wechalekar A; Palladini G
Amyloid; 2022 Mar; 29(1):1-7. PubMed ID: 34783272
[TBL] [Abstract][Full Text] [Related]
3. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
4. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
5. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
[TBL] [Abstract][Full Text] [Related]
7. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
[TBL] [Abstract][Full Text] [Related]
9. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis.
Nguyen VP; Brauneis D; Kaku M; Sloan JM; Sarosiek S; Quillen K; Shelton AC; Sanchorawala V
Bone Marrow Transplant; 2018 Mar; 53(3):371-373. PubMed ID: 29269794
[No Abstract] [Full Text] [Related]
10. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
11. [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
Mukai S; Kanashima H; Ogawa Y; Nakao T; Teshima H; Yamane T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):625-7. PubMed ID: 22504689
[TBL] [Abstract][Full Text] [Related]
12. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
[TBL] [Abstract][Full Text] [Related]
16. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
[TBL] [Abstract][Full Text] [Related]
17. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
Vaxman I; Dispenzieri A
Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
[TBL] [Abstract][Full Text] [Related]
18. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
19. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
